Biosimilar Uptake in Medicare Advantage vs Traditional Medicare-Reference-Cited by-同舟云学术

Biosimilar Uptake in Medicare Advantage vs Traditional Medicare

Published:2023-12-28 Issue:12 Volume:4 Page:e234335
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Kozlowski Steven¹,Kwist Andrew²,McEvoy Rowan²,Koirala Nirabh²,Chillarige Yoganand²,Kelman Jeffrey A.³,Graham David J.¹

Affiliation:

1. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

2. Acumen LLC, Burlingame, California

3. Centers for Medicare & Medicaid Services, Washington, DC

Abstract

This cross-sectional study uses Traditional Medicare and Medicare Advantage claims data to evaluate uptake of biosimilars relative to their reference products.

Publisher

American Medical Association (AMA)

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2813299/kozlowski_2023_ld_230036_1702577727.30785.pdf

Reference6 articles.

1. Uptake and competition among biosimilar biological products in the US Medicare fee-for-service population.;Kozlowski;J Gen Intern Med,2022

2. Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare.;Anderson;Health Serv Res,2022

3. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.;Martin;N Engl J Med,2011

4. Differences between managed care and fee-for-service Medicaid in the use of generics for high-rebate drugs: the cases of insulin glargine and glatiramer.;Hernandez;J Manag Care Spec Pharm,2020

5. USFDA. Purple Book: Lists of Licensed Biological Products With Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Accessed March 1, 2023. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024